Weight Loss Drugs

The Weight Loss Drugs theme covers pharmacologic therapies targeting obesity and metabolic disorders, spanning prescription anti-obesity agents and adjacent metabolic indications. Core tracks include incretin-based therapies (GLP-1, GIP/GLP-1 co-agonists), next-generation multi-agonists and amylin analogs, oral and long-acting formulations, lifecycle and combo strategies, plus manufacturing scale-up and access dynamics across diabetes, cardiovascular risk, and NASH comorbidities.The sector's total market cap is 1637.03 billion USD, with a 24h change of +0.33%. Among 5 constituents, 4 are up (80.00%) and 1 are down (20.00%). The top gainer is Novo-Nordisk A/S (NVO), with a 24h increase of +1.88%.Sector shows a mild upward bias with leaders in control and healthy breadth. Trade leaders on dips; accumulate around earnings catalysts while monitoring pricing and regulatory signals.